JP2025500412A5 - - Google Patents

Info

Publication number
JP2025500412A5
JP2025500412A5 JP2024537896A JP2024537896A JP2025500412A5 JP 2025500412 A5 JP2025500412 A5 JP 2025500412A5 JP 2024537896 A JP2024537896 A JP 2024537896A JP 2024537896 A JP2024537896 A JP 2024537896A JP 2025500412 A5 JP2025500412 A5 JP 2025500412A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
qol
patient
questionnaire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/082213 external-priority patent/WO2023122713A1/en
Publication of JP2025500412A publication Critical patent/JP2025500412A/ja
Publication of JP2025500412A5 publication Critical patent/JP2025500412A5/ja
Pending legal-status Critical Current

Links

JP2024537896A 2021-12-22 2022-12-22 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン Pending JP2025500412A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163293070P 2021-12-22 2021-12-22
US63/293,070 2021-12-22
US202263305550P 2022-02-01 2022-02-01
US63/305,550 2022-02-01
US202263335535P 2022-04-27 2022-04-27
US63/335,535 2022-04-27
US202263359717P 2022-07-08 2022-07-08
US63/359,717 2022-07-08
US202263382223P 2022-11-03 2022-11-03
US63/382,223 2022-11-03
US202263386489P 2022-12-07 2022-12-07
US63/386,489 2022-12-07
PCT/US2022/082213 WO2023122713A1 (en) 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients

Publications (2)

Publication Number Publication Date
JP2025500412A JP2025500412A (ja) 2025-01-09
JP2025500412A5 true JP2025500412A5 (cg-RX-API-DMAC7.html) 2026-01-05

Family

ID=85227438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537896A Pending JP2025500412A (ja) 2021-12-22 2022-12-22 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン

Country Status (10)

Country Link
US (1) US20250064842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452280A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500412A (cg-RX-API-DMAC7.html)
KR (1) KR20240138572A (cg-RX-API-DMAC7.html)
AU (1) AU2022419588A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243297A1 (cg-RX-API-DMAC7.html)
IL (1) IL313677A (cg-RX-API-DMAC7.html)
MX (1) MX2024007894A (cg-RX-API-DMAC7.html)
TW (1) TW202342065A (cg-RX-API-DMAC7.html)
WO (1) WO2023122713A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物
WO2022120291A1 (en) * 2020-12-06 2022-06-09 Genzyme Corporation Treatment of hemophilia with fitusiran

Similar Documents

Publication Publication Date Title
JP2023531679A5 (cg-RX-API-DMAC7.html)
Lai et al. Recombinant interferon‐α in inoperable hepatocellular carcinoma: a randomized controlled trial
Janson et al. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours
Protzer et al. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C
ES2555279T3 (es) Neuroprotección en enfermedades desmielinizantes
ES2235499T3 (es) Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.
JP2022123073A (ja) Efpの治療または低減方法
CA2542726A1 (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
CN1094642A (zh) 治疗组合物
WO2011079175A1 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
Shayan et al. Use of propranolol in treating hemangiomas
TW202417035A (zh) 提派肽(tirzepatide)組合物及用途
JP2002510645A5 (cg-RX-API-DMAC7.html)
WO2022039619A1 (ru) Противовирусное средство для комбинированной терапии covid-19 (sars-cov-2)
JP2023544249A5 (cg-RX-API-DMAC7.html)
RU2024120372A (ru) Фитусиран для применения в улучшении сообщаемого пациентом исхода у пациентов с гемофилией
WO2023028554A1 (en) Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection
ES2929379T3 (es) Métodos para el tratamiento de infecciones por coronavirus
Neal The treatment of acute infections of the central nervous system with sulfanilamide
JP2025500412A (ja) 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン
BABAMAHMOODI et al. Combination Therapy with Remdisivir and Tocilizumab for COVID-19: Lessons for Futures Studies (Case Report)
KR20000010880A (ko) 종양에 대한 숙주 방어 기작의 자극
RU2389499C1 (ru) Способ лечения больных с гипербилирубинемией
Loewe et al. The Prolonging Action of Penicillin by Para-Aminohippuric Acid.
RU2416413C1 (ru) Средство для лечения кровопотери ("спаскровь")